BioMarin Pharmaceutical (BMRN)River Road Asset Management, LLC reduced its stake -375K shares

543K

Shares reported · -375K vs prior quarter

0.35%

Disclosed portfolio weight

$31.1M

Reported value

Holdings as of

Jun 30, 2026

Filed

Jul 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 2, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 2, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the Company) held its 2026 Annual Meeting of Stockholders (the Annual Meeting).”

What came next

1. Aug 6, 2026Company filing · Form 8-K · ResultsReported its results
2. Aug 17, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
3. Aug 30, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
4. Sep 2, 2026Insider · 8 days before an 8-KOfficer sold ~$1.16M of BMRN shares in the open market
5. Sep 10, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026 (the Appointment Date).”
6. Sep 24, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
7. Oct 6, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for BioMarin Pharmaceutical

For BioMarin Pharmaceutical, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 9 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BMRN page.

How this filing works

• SEC Form 13F

Other disclosures at BioMarin Pharmaceutical

• SEC Form 4Sep 3, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its BMRN page.